Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies-Reference-Cited by-同舟云学术

Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Published:2020-12-22 Issue:2 Volume:112 Page:725-733
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Minami Hironobu¹^ORCID,Doi Toshihiko²,Toyoda Masanori¹,Imamura Yoshinori¹^ORCID,Kiyota Naomi¹,Mitsuma Ayako³,Shimokata Tomoya³,Naito Yoichi²^ORCID,Matsubara Nobuaki²,Tajima Takeshi⁴,Tokushige Kota⁴,Ishihara Kae⁴,Cameron Scott⁵,Ando Yuichi³^ORCID

Affiliation:

1. Kobe University Graduate School of Medicine and Hospital Kobe Japan

2. National Cancer Center Hospital East Kashiwa Japan

3. Nagoya University Hospital Nagoya Japan

4. Novartis Pharma KK Tokyo Japan

5. Novartis Institutes for BioMedical Research Cambridge MA USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14678

Reference24 articles.

1. PD-1 and Its Ligands in Tolerance and Immunity

2. The blockade of immune checkpoints in cancer immunotherapy

3. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

4. PD-1 signaling in primary T cells

5. KEYTRUDA (pembrolizumab).Highlights of Prescribing Information MSD International GmbH (revised 06/2018);2014.https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed June 2020.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12);OncoImmunology;2024-06-24

2. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy;Livers;2023-03-13

3. Phage Display Technology as a Powerful Platform for Antibody Drug Discovery;Viruses;2021-01-25

4. The role of immune checkpoint inhibitors in triple-negative breast cancer: recent developments and future perspectives;Journal of Cancer Metastasis and Treatment;2021